High Content Screening (HCS) Market 2022-2032: Global Industry Analysis and Opportunity Assessment

Future Market Insights (FMI) in its new report, titled, “High Content Screening (HCS) Market: Global Industry Analysis and Opportunity Assessment 2015-2025“, provides key insights on the prospects of leading players in the high content screening market. According to FMI, leading companies, such as Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., and GE Healthcare, Olympus Corporation, and PerkinElmer Inc. are anticipated to gain traction owing to increased demand for high content screening systems in the near future.

For more insights into the market, request a sample of this?report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-426 

Becton, Dickinson and Company (BD) provides HCS systems for application in medical, diagnostics, and biosciences, and has a strong presence in the U.S. and Europe. According to FMI’s research, the U.S. and Europe accounted for nearly 73% of revenue for BD in 2014. The company is focusing on consolidating its position in the global HCS market through partnerships and joint ventures. BD acquired CareFusion in March 2015 to position itself more strongly in the lucrative high content screening market. The company recently realigned its medical, diagnostics, and biosciences segment into life sciences and medical to extend its solutions across the management process for companies, hospitals, and individuals.

Thermo Fisher Scientific Inc., whose line of offerings includes laboratory products and services, life sciences solutions, specialty diagnostics, and analytical instruments, is focusing on research and development (R&D) of new products and business segments to gain market share and incremental growth. The company invested US$ 691 Mn on R&D initiatives in 2014. FMI expects the company to continue with its current approach during the forecast period 2015-2025.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-426 
GE Healthcare, which has a sizeable presence in North America, Europe, and Asia Pacific, relies on its world-class data and analytics capability to expand its presence in the emerging market. The company acquired part of Thermo Fisher Scientific Inc.’s life science business for approximately US$ 1.1 Bn in March, 2014.

Tokyo-based Olympus Corporation’s business strategy is identifying and liquidating non-core businesses to improve its manufacturing capabilities. According to FMI, the company is planning to invest US$ 175 Mn over 2015 to strengthen its sales force and R&D capabilities.

PerkinElmer Inc., which provides diagnostic tools and analytical technology solutions for human and environmental health, is focusing on continuous innovation through collaboration and licensing to strengthen its core business segments. According to FMI, the company announced alignment of its business into multi-vendor service in a bid to expand its services develop value-added applications and solutions.

The global high content screening market is estimated to reach US$ 382.9 Mn by 2025, owing to application of high content screening in toxicity studies and drug discovery. Support from government for life sciences research and establishment of research-based biotechnologies industries in the lucrative markets of China and India is expected to provide opportunities to the high content screening companies.

The key end-use application segments of high content screening (HCS) market include primary and secondary screening, toxicity studies, target identification and validation, and compound profiling. Among these, application of high content screening is robust in the primary and secondary screening; FMI estimates this segment to account for a share of 36.6% by 2025 of the global HCS market, registering a CAGR of 6% during the forecast period 2015-2025. Other key segment-target identification and validation-is anticipated to account for a market share of 26.6% by 2025.

Pharmaceutical and healthcare, educational institutions, independent CRO, biotechnology, and government organisations are the key end-use industries where high content screening systems are used. Among these, FMI projects the biotechnology segment to witness the fastest CAGR during the forecast period.

Key stakeholders in the high content screening market are eyeing the lucrative opportunities in North America and Western Europe to consolidate their position in the market. The high content screening market in North America and Western Europe are anticipated to witness a CAGR of 6% and 6.2% respectively during the forecast period 2015-2025.